Biogen is a high-quality, cash-generative biotech (Piotroski 9/9, 233% FCF/NI) with strong momentum, but the price already sits 4.4% above the analyst target near its 52-week high, leaving little room to add.
Thesis pillars
- High Quality Cash Conversion↓Deteriorating
- Price Above Analyst Target↑Improving
- Strong Momentum Near High↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 6, 2026
Biogen Inc. (BIIB) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $254.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.7% away).
Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for SMA, SKYCLARYS for FA, QALSODY for ALS), and co-commercializes LEQEMBI for Alzheimer's with Eisai. Revenue comes from product sales plus financial rights to... Read more
Hold if already holding. Not a fresh buy at $254.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.7% away). Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 92d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Biogen Inc.
About Biogen Inc.
Biogen markets approved drugs including TYSABRI and SPINRAZA, each accounting for more than 10% of total revenue in fiscal year 2025, across multiple sclerosis, rare neurological diseases, and Alzheimer's disease in the U.S. and international markets. LEQEMBI, co-commercialized with Eisai, received European Commission approval in April 2025 and MHRA approval in the UK in November 2025. Alcyone Therapeutics was acquired in November 2025 for approximately $85 million to advance intrathecal delivery platforms for SPINRAZA.
Biogen generates revenue through direct product sales of prescription medicines in MS and rare-disease portfolios, financial rights to Genentech/Roche anti-CD20 therapies including RITUXAN and OCREVUS, and a 50% share of LEQEMBI net sales under the Eisai collaboration. Distribution relies on specialty pharmacy channels and hospital networks, with reimbursement subject to commercial insurers, Medicare, and Medicaid. The pipeline includes felzartamab, with Phase 3 studies in IgA nephropathy (PREVAIL) and primary membranous nephropathy (PROMINENT) both initiating patient dosing in June 2025, and zorevunersen, whose Phase 3 EMPEROR study in Dravet syndrome dosed its first patient in August 2025 under the Stoke Therapeutics collaboration funded by a $165 million upfront payment.
Show full overview
Biogen faces pricing pressure from two concurrent policy mechanisms: the Inflation Reduction Act's Medicare drug-price negotiation authority and the current administration's most-favored-nation executive order, which could tie U.S. drug prices to those in lower-cost countries. The OBBBA, signed into law in July 2025, introduces additional Medicaid eligibility constraints effective in 2027 and 2028, and the company has stated it cannot determine the overall impact on operations. For MS therapies with substantial Medicare reliance, these mechanisms may weigh on net realized pricing over the medium term.
See also: Healthcare · Drug Manufacturers - General
From Biogen Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — Biogen Inc.
Latest news
- NEWS Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash Flow - Yahoo Finance — Yahoo Finance Oct 29, 2026 negative
- NEWS Why Biogen Stock Topped the Market Today - The Motley Fool — The Motley Fool Jul 29, 2026 positive
- NEWS Why Biogen Stock Topped the Market Today - Yahoo Finance — Yahoo Finance Jul 29, 2026 positive
- NEWS Why Biogen Stock Topped the Market Today - finance.yahoo.com — finance.yahoo.com Jul 29, 2026 positive
- NEWS Oppenheimer reiterates Biogen stock rating on strong quarter - Investing.com — Investing.com Jul 29, 2026 positive
Latest item Oct 29, 2026 · Generated 2026-11-05T11:39:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWProductTYSABRI10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025'
- LOWProductSPINRAZA10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-03-11Item 5.02MEDIUMChief Legal Officer Susan H. Alexander to depart effective end of May 2026. Company initiated search for next Chief Legal Officer. No reason cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $254.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.7% away). Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Analyst target $243.64 reached (−4.3%), stop $237.94 (−6.9%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Analyst target $243.64 reached (−4.3% from $254.46); no take-profit level is published. Analyst target $243.64 reached (−4.3%), stop $237.94 (−6.9%), A.R:R -0.3:1. Stop-loss: $237.94.
Analyst target reached - limited upside remaining; Near 52-week high (1.7% away).
Biogen Inc. trades at a P/E of 110.2 (forward 15.6). TrendMatrix value score: 4.6/10. Verdict: Hold.
44 analysts rate BIIB, with a consensus score of 4.0/5. 32 analysts publish price targets averaging $265.
What does Biogen Inc. do?Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for...
Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for SMA, SKYCLARYS for FA, QALSODY for ALS), and co-commercializes LEQEMBI for Alzheimer's with Eisai. Revenue comes from product sales plus financial rights to anti-CD20 therapies via a Genentech collaboration.